Thyroid Cancer

Latest News

Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer
Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

November 1st 2024

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.
Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

October 16th 2024

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.
Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

October 8th 2024

The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.
FDA Approves Selpercatinib for RET Fusion+ Medullary Thyroid Cancer

September 27th 2024

“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS
Taking a Multidisciplinary Approach to Thyroid Cancer Treatment

September 27th 2024